论文部分内容阅读
目的探讨阿托伐他汀治疗心肌梗死后无症状心力衰竭(心衰)患者的临床效果。方法 80例心肌梗死后无症状心衰患者,随机分为研究组和对照组,每组40例。对照组患者采用常规治疗方法治疗,研究组患者在对照组基础上采用阿托伐他汀进行治疗。比较两组治疗效果。结果研究组患者治疗后血浆N-末端脑钠肽前体(NT-pro BNP)水平为(412.32±162.45)pg/ml,低于对照组的(548.47±163.57)pg/ml,差异有统计学意义(P<0.05)。治疗后,研究组患者左室舒张末期内径、左室收缩末期内径、左心室射血分数指标均优于对照组,差异有统计学意义(P<0.05)。结论采用阿托伐他汀治疗心肌梗死后无症状心衰患者有显著的效果,值得临床推广应用。
Objective To investigate the clinical effect of atorvastatin on patients with asymptomatic heart failure (CHF) after myocardial infarction. Methods 80 patients with asymptomatic heart failure after myocardial infarction were randomly divided into study group and control group, 40 cases in each group. Patients in the control group were treated with conventional treatment. Patients in the study group were treated with atorvastatin on the basis of the control group. Compare the treatment effect of two groups. Results The level of plasma NT-pro BNP in the study group was (412.32 ± 162.45) pg / ml after treatment, which was lower than that of the control group (548.47 ± 163.57) pg / ml, the difference was statistically significant Significance (P <0.05). After treatment, left ventricular end-diastolic diameter, left ventricular end-systolic diameter and left ventricular ejection fraction in study group were significantly better than those in control group (P <0.05). Conclusion Atorvastatin treatment of patients with asymptomatic heart failure after myocardial infarction has a significant effect, it is worthy of clinical application.